Drug Trial Radar · NCT06394518
Phase 1, Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants
Last checked: Nov 20, 2026Latest source record: May 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Jul 7, 2022
Primary completion
Feb 24, 2023
Study completion Feb 24, 2023
Sponsor
- Lead sponsor
- TenNor Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- May 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase 1, single-center, randomized, double-blind, placebo-controlled, dose-escalation clinical trial of single and multiple intravenous doses of TNP-2092 for injection in healthy Chinese participants.
Conditions
- Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
- Prosthetic Joints Infection (PJI)
Interventions
TNP-2092 for injectionDrug
The study had 3 dose groups, a 200 mg single dose group (low-dose group), a 300 mg single and multiple dose continuous dose group (medium-dose group), and 400 mg single dose group (high-dose group)
placeboDrug
The placebo for TNP-2092 active drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Adverse Events (AEs)Time frame: Day 1 to Day 14
- Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf)Time frame: 10, 20, 30, 45 minutes, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72 hours after the end of infusion
- Area Under the Plasma Concentration Versus Time Curve from 0 to the Last Measurable Concentration (AUC0-last)Time frame: 10, 20, 30, 45 minutes, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72 hours after the end of infusion
- Maximum Observed Plasma Concentration (Cmax) of TNP-2092Time frame: 10, 20, 30, 45 minutes, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72 hours after the end of infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.